Celon Pharma S.A. (WSE:CLN)
21.35
-0.10 (-0.47%)
At close: Dec 5, 2025
Celon Pharma Ratios and Metrics
Market cap in millions PLN. Fiscal year is January - December.
Millions PLN. Fiscal year is Jan - Dec.
Fiscal Year | Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 4, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Market Capitalization | 1,150 | 1,425 | 789 | 716 | 1,691 | 1,825 | Upgrade
|
| Market Cap Growth | -19.13% | 80.47% | 10.32% | -57.68% | -7.35% | 2.14% | Upgrade
|
| Enterprise Value | 1,143 | 1,336 | 704 | 578 | 1,487 | 1,807 | Upgrade
|
| Last Close Price | 21.35 | 26.45 | 15.38 | 13.87 | 32.20 | 39.31 | Upgrade
|
| Forward PE | - | 35.84 | - | - | - | 39.52 | Upgrade
|
| PS Ratio | 5.10 | 6.93 | 3.68 | 3.69 | 8.62 | 11.59 | Upgrade
|
| PB Ratio | 2.95 | 3.20 | 1.77 | 1.49 | 3.05 | 5.30 | Upgrade
|
| P/TBV Ratio | 2.98 | 3.26 | 1.83 | 1.56 | 3.21 | 5.96 | Upgrade
|
| P/FCF Ratio | - | - | - | - | 650.25 | - | Upgrade
|
| P/OCF Ratio | 2430.94 | - | - | - | 38.47 | 25.44 | Upgrade
|
| EV/Sales Ratio | 5.07 | 6.50 | 3.28 | 2.98 | 7.59 | 11.48 | Upgrade
|
| EV/EBITDA Ratio | - | - | 81.54 | - | 53.42 | 70.90 | Upgrade
|
| EV/FCF Ratio | -27.72 | - | - | - | 572.04 | - | Upgrade
|
| Debt / Equity Ratio | 0.04 | 0.04 | 0.06 | 0.06 | 0.03 | 0.07 | Upgrade
|
| Debt / EBITDA Ratio | - | - | 1.24 | 5.92 | 0.52 | 1.00 | Upgrade
|
| Debt / FCF Ratio | - | - | - | - | 5.74 | - | Upgrade
|
| Asset Turnover | 0.41 | 0.37 | 0.35 | 0.29 | 0.32 | 0.28 | Upgrade
|
| Inventory Turnover | 2.82 | 2.23 | 2.06 | 2.15 | 2.32 | 1.23 | Upgrade
|
| Quick Ratio | 1.38 | 1.90 | 1.89 | 1.70 | 2.95 | 0.75 | Upgrade
|
| Current Ratio | 1.90 | 2.40 | 2.20 | 2.04 | 3.23 | 1.05 | Upgrade
|
| Return on Equity (ROE) | -27.03% | -7.73% | -6.08% | -7.60% | -2.58% | -0.23% | Upgrade
|
| Return on Assets (ROA) | -12.83% | -5.94% | -2.92% | -3.51% | -1.07% | -0.46% | Upgrade
|
| Return on Capital (ROIC) | -14.99% | -7.09% | -3.62% | -4.41% | -1.41% | -0.63% | Upgrade
|
| Return on Capital Employed (ROCE) | -26.90% | -11.10% | -5.90% | -7.20% | -1.70% | -1.00% | Upgrade
|
| Earnings Yield | -10.64% | -2.42% | -3.56% | -5.49% | -0.69% | -0.05% | Upgrade
|
| FCF Yield | -3.59% | -2.40% | -5.21% | -5.40% | 0.15% | -1.52% | Upgrade
|
| Dividend Yield | - | - | 0.52% | 0.65% | 0.90% | 0.18% | Upgrade
|
| Buyback Yield / Dilution | 1.18% | -2.86% | -0.04% | -9.32% | -3.74% | - | Upgrade
|
| Total Shareholder Return | 1.18% | -2.86% | 0.48% | -8.67% | -2.84% | 0.18% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.